Azitra Q2 net loss widens to $3.3M; pauses ATR-12, advances ATR-COSF and ATR-04

Azitra, Inc.

2026-Q2 EPS reported -$0.42

Net loss $3.3M in Q2 2026 vs $2.9M in Q2 2025; G&A up to $2.1M from $1.5M.
Cash and cash equivalents $6.7M as of June 30, 2026.
ATR-COSF: positive preclinical repeat-dose delivery and anti-wrinkle data in ex vivo human skin; proof-of-concept cosmetic study planned Q3 2026.
ATR-04: continuing Phase 1/2 enrollment (6 sites incl. MD Anderson); topline data from first cohort expected Q4 2026.
ATR-12 Netherton syndrome Phase 1b enrollment paused for capital allocation discipline.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.